GlassScriptPhysician profile
Kimberly S Ewing
NPI 1528361417
$4,289.13
in general payments reported to CMS, 2019-2025
24 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $605 · 2022: $1,109 · 2023: $1,274 · 2024: $1,002 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,386 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,386.22 |
| Education | $188.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,052.60 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $562.16 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $536.14 | 2021-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Pulmonx Corporation | $396.16 | 2022-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Genzyme Corporation | $284.82 | 2021-2025 | |
| Mylan Specialty L.P. | $260.93 | 2022-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.95 | 2021-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $182.93 | 2021-2024 | Glassia |
| Grifols USA, LLC | $142.05 | 2022-2024 | Prolastin-C Liquid |
| Insmed, INC. | $140.09 | 2021 | |
| Abbvie INC. | $90.20 | 2022-2025 | |
| Amgen INC. | $74.73 | 2022-2025 | Tezspire |
| Electromed, INC. | $73.72 | 2024-2025 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $53.55 | 2022 | |
| La Jolla Pharmaceutical Company | $40.15 | 2021-2023 | Xerava |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $32.75 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $31.97 | 2023 | |
| Janssen Pharmaceuticals, INC | $25.34 | 2021-2022 | |
| Ethicon US, LLC | $23.63 | 2022 | |
| Shionogi INC | $22.42 | 2023 | Fetroja |
| Viatris Specialty LLC | $21.85 | 2025 | Yupelri |
| Madrigal Pharmaceuticals | $21.33 | 2025 | Rezdiffra |
| Jazz Pharmaceuticals INC. | $18.79 | 2024 | |
| United Therapeutics Corporation | $16.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Ewing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.